Form 4 for INAB IN8BIO, INC.
Accepted 2024-10-08 00:00:00 ET · period of report 2024-10-04 · accession 0001415889-24-024869 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-10-08 | 2024-10-04 | INAB | McCall Patrick | CFO | A - Grant | — | +25.3K | 52.1K | +95% | — |
| D | 2024-10-08 | 2024-10-04 | INAB | McCall Patrick | CFO | D - Sale to Iss | — | -20.5K | 0 | -100% | — |
| DM | 2024-10-08 | 2024-10-04 | INAB | McCall Patrick | CFO | A - Grant | — | +45.8K | 20.5K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-10-04 | A | A | 25,316 | — | 52,071 | D | — | — | (F1) The reported securities are included within 25,316 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 25,316 shares of common stock. |
| 2 | Derivative | Series A Warrants (right to buy) | 2024-10-04 | D | D | 20,492 | — | 0 | D | $1.25 · — to 2025-06-13 | 20,492 Common Stock | (F4) The reported securities are included within 20,492 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 20,492 shares of common stock. (F2) The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025. (F3) Fully vested and exercisable. |
| 3 | Derivative | Series C Warrants (right to buy) | 2024-10-04 | A | A | 25,316 | — | 25,316 | D | $0.27 · — to 2027-10-04 | 25,316 Common Stock | (F1) The reported securities are included within 25,316 Issuer Units purchased by the Reporting Person for $0.395 per Unit. Each Unit consists of one share of common stock and one Series C warrant representing the right to purchase 25,316 shares of common stock. (F3) Fully vested and exercisable. |
| 4 | Derivative | Series A Warrants (right to buy) | 2024-10-04 | A | A | 20,492 | — | 20,492 | D | $0.45 · — to 2025-10-04 | 20,492 Common Stock | (F4) The reported securities are included within 20,492 Issuer Units purchased by the Reporting Person for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 20,492 shares of common stock. (F2) The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.25 and expiration date of June 13, 2025. The exercise price was reduced to $0.45 and the warrant expiration date was extended to October 4, 2025. (F3) Fully vested and exercisable. |